A
Admir Malaj
Researcher at University of Medicine, Tirana
Publications - 15
Citations - 315
Admir Malaj is an academic researcher from University of Medicine, Tirana. The author has contributed to research in topics: Medical prescription & Antibiotic misuse. The author has an hindex of 8, co-authored 14 publications receiving 198 citations.
Papers
More filters
Journal ArticleDOI
Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries.
Tomasz Bochenek,Vafa Abilova,Ali Alkan,Bogdan Asanin,Iñigo de Miguel Beriain,Zeljka Besovic,Patricia Vella Bonanno,Anna Bucsics,Michal Davidescu,Elfi De Weerdt,Natasa Duborija-Kovacevic,Jurij Fürst,Mina Gaga,Elma Gailīte,Jolanta Gulbinovič,Emre Umut Gürpinar,Balázs Hankó,Vincent Hargaden,Tor A. Hotvedt,Iris Hoxha,Isabelle Huys,András Inotai,Arianit Jakupi,Helena Jenzer,Roberta Joppi,Ott Laius,Marie-Camille Lenormand,Despina Makridaki,Admir Malaj,Kertu Margus,Vanda Marković-Peković,Vanda Marković-Peković,Nenad Miljković,João Luís de Miranda,João Luís de Miranda,Stanislav Primožič,Dragana Rajinac,David G. Schwartz,Robin Šebesta,Steven Simoens,Juraj Slaby,Ljiljana Sović-Brkičić,Tomas Tesar,Leonidas Tzimis,Ewa Warmińska,Brian Godman,Brian Godman,Brian Godman +47 more
TL;DR: The characteristics of drug shortages, including their assortment, duration, frequency, and dynamics, were found to be variable and sometimes difficult to assess and there was an urgent need to develop a set of agreed definitions for drug shortages.
Journal ArticleDOI
Are pharmacists' good knowledge and awareness on antibiotics taken for granted? The situation in Albania and future implications across countries.
Iris Hoxha,Admir Malaj,Besmira Kraja,Silvia Bino,Margaret Oluka,Vanda Marković-Peković,Brian Godman +6 more
TL;DR: Signs regarding pharmacists' knowledge of antibiotics in Albania are encouraging and concerns are concerns; however, concerns are raised about educational programmes among patients and pharmacists and greater enforcement of legislation.
Journal ArticleDOI
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
Brian Godman,Andrew Hill,Steven Simoens,Gisbert Selke,Iva Selke Krulichová,Carolina Zampirolli Dias,Antony P. Martin,Wija Oortwijn,Angela Timoney,Lars L. Gustafsson,Luka Voncina,Hye-Young Kwon,Jolanta Gulbinovič,Dzintars Gotham,Janet Wale,Wania Cristina Silva,Tomasz Bochenek,Eleonora Allocati,Amanj Kurdi,Olayinka O Ogunleye,Johanna C Meyer,Iris Hoxha,Admir Malaj,Christian Hierländer,Robert Sauermann,Wouter Hamelinck,Guenka Petrova,Ott Laius,Irene Langner,John Yfantopoulos,Roberta Joppi,Arianit Jakupi,Ieva Greiciute-Kuprijanov,Patricia Vella Bonanno,Jf Hans Piepenbrink,Vincent de Valk,Magdalene Wladysiuk,Vanda Marković-Peković,Ileana Mardare,Jurij Fürst,D Tomek,Merce Obach Cortadellas,Corinne Zara,Caridad Pontes,Stuart McTaggart,Tracey-Lea Laba,Øyvind Melien,Durhane Wong-Rieger,Seung Jin Bae,Ruaraidh Hill +49 more
TL;DR: In this paper, a number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models.
Journal ArticleDOI
The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures.
Evelien Moorkens,Brian Godman,Brian Godman,Brian Godman,Isabelle Huys,Iris Hoxha,Admir Malaj,Simon Keuerleber,Silvia Stockinger,Sarah Mörtenhuber,Maria Dimitrova,Konstantin Tachkov,Luka Voncina,Vera Vlahović Palčevski,Gnosia Achniotou,Juraj Slabý,Leona Popelková,Kateřina Kohoutová,Dorthe Bartels,Ott Laius,Jaana E. Martikainen,Gisbert Selke,Vasileios Kourafalos,Einar Magnusson,Rannveig Einarsdóttir,Roisin Adams,Roberta Joppi,Eleonora Allocati,Arianit Jakupi,Anita Viksna,Ieva Greičiūtė-Kuprijanov,Patricia Vella Bonanno,Vincent Suttorp,Øyvind Melien,Robert Plisko,Ileana Mardare,Dmitry Meshkov,Tanja Novakovic,Jurij Fürst,Corinne Zara,Vanda Marković-Peković,Nataša Grubiša,Gustaf Befrits,Robert Puckett,Arnold G. Vulto,Arnold G. Vulto +45 more
TL;DR: A European overview of (list) prices of originator adalimumab, before and after loss of exclusivity; to report changes in the reimbursement status of ad alimumab products; and discuss relevant policy measures.
Journal ArticleDOI
Pricing of oral generic cancer medicines in 25 European countries; findings and implications
Brian Godman,Andrew F. Hill,Steven Simoens,Amanj Kurdi,Jolanta Gulbinovič,Antony P. Martin,Angela Timoney,Dzintars Gotham,Janet Wale,Tomasz Bochenek,Celia C. Rothe,Iris Hoxha,Admir Malaj,Christian Hierländer,Robert Sauermann,Wouter Hamelinck,Zornitza Mitkova,Guenka Petrova,Ott Laius,Catherine Sermet,Irene Langer,Gisbert Selke,John Yfantopoulos,Roberta Joppi,Arianit Jakupi,Elita Poplavska,Ieva Greiciute-Kuprijanov,Patricia Vella Bonanno,JF (Hans) Piepenbrink,Vincent de Valk,Carolin Hagen,Anne Marthe Ringerud,Robert Plisko,Magdalene Wladysiuk,Vanda Marković-Peković,Nataša Grubiša,Tatjana Ponorac,Ileana Mardare,Tanja Novakovic,Mark Parker,Jurij Fürst,D Tomek,Merce Obach Cortadellas,Corinne Zara,Maria Juhasz-Haverinen,Peter Skiold,Stuart McTaggart,Alan Haycox +47 more
TL;DR: The considerable price reductions seen for some generics means health authorities should further encourage the use of generic oncology medicines when they become available to fund increased volumes and new valued cancer medicines.